Stocks and Investing Stocks and Investing
Wed, December 15, 2021
Tue, December 14, 2021
Mon, December 13, 2021
Sun, December 12, 2021
Fri, December 10, 2021
Thu, December 9, 2021

Hartaj Singh Upgraded (SRPT) to Buy and Held Target at $125 on, Dec 9th, 2021


Published on 2024-10-27 18:55:53 - WOPRAI, Hartaj Singh
  Print publication without navigation


Hartaj Singh of Oppenheimer, Upgraded "Sarepta Therapeutics, Inc." (SRPT) to Buy and Held Target at $125 on, Dec 9th, 2021.

Hartaj has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 2 agree with Hartaj's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Judah Frommer of "Credit Suisse" Maintained at Hold with Decreased Target to $95 on, Friday, October 15th, 2021
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $90 on, Monday, August 16th, 2021


These are the ratings of the 5 analyists that currently disagree with Hartaj


  • Anupam Rama of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $130 on, Friday, November 5th, 2021
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $145 on, Thursday, November 4th, 2021
  • Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $157 on, Thursday, November 4th, 2021
  • Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $125 on, Tuesday, October 12th, 2021
  • Whitney Ijem of "Guggenheim" Upgraded from Hold to Strong Buy on, Wednesday, September 15th, 2021